By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists generally agreed that while RZG's higher fees and momentum-driven strategy have led to superior short-term returns, its higher risk, concentration, and potential tax drag make it a less attractive long-term option compared to the cheaper, more diversified ISCG.
Risk: Concentration risk and potential tax drag from high turnover in RZG
Opportunity: ISCG's lower fees and broader diversification
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The iShares Morningstar Small-Cap Growth ETF (NYSEMKT:ISCG) provides a low-cost, highly diversified approach to small-cap growth, while the Invesco S&P SmallCap 600 Pure Growth ETF (NYSEMKT:RZG) offers a more concentrated strategy.
Both funds target the small-cap growth segment but build their portfolios in different ways. ISCG follows a traditional market-cap-weighted index of small companies, while RZG screens the S&P SmallCap 600 for stocks with the strongest growth characteristics -- such as sales growth, earnings momentum, and price momentum -- and weights its holdings accordingly.
| Metric | RZG | ISCG | |---|---|---| | Issuer | Invesco | iShares | | Expense ratio | 0.35% | 0.06% | | 1-year return (as of July 9, 2026) | 38.84% | 27.53% | | Dividend yield | 0.42% | 0.57% | | Beta | 1.04 | 1.22 | | AUM | $135.9 million | $1.0 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
ISCG is significantly cheaper, with an expense ratio of 0.06%, compared to RZG’s 0.35%. ISCG also offers a slightly higher dividend yield of 0.57%, compared to RZG's 0.42% -- a modest edge for income-minded investors.
| Metric | RZG | ISCG | |---|---|---| | Max drawdown (5 yr) | (38.33%) | (41.47%) | | Growth of $1,000 over 5 years (total return) | $1,375 | $1,298 |
Launched in 2004, ISCG tracks a broad index of small-cap growth stocks. The fund has heavy concentrations in industrials and technology at 23.9% and 22.5%, respectively, as well as healthcare at 17.9%. With 933 holdings, it offers extensive diversification, minimizing individual stock risk. Its largest positions include Sterling Infrastructure (NASDAQ:STRL) at 0.8%, Okta (NASDAQ:OKTA) at 0.7%, and Guardant Health (NASDAQ:GH) at 0.6%.
RZG provides a narrower portfolio of 125 stocks, built from the S&P SmallCap 600 index. This index uses a growth-score methodology that favors companies with strong sales growth, earnings momentum, and price momentum. Its top sector allocations are healthcare at 25.1%, technology at 17.3%, and industrials at 16.4%. RZG’s approach leads to higher concentration than ISCG's, with top holdings including ACM Research (NASDAQ:ACMR) at 3.7%, Powell Industries (NASDAQ:POWL) at 2.0%, and Argan (NYSE:AGX) at 2.0%. RZG fund was launched in 2006.
For more guidance on ETF investing, check out the full guide at this link.
The choice between these two funds really comes down to how much an investor is willing to pay for the potential to outperform.
Cost is almost always a primary consideration when two funds target a similar corner of the market. ISCG's 0.06% expense ratio is about as cheap as small-cap investing gets -- on a $10,000 investment, ISCG charges roughly $6 a year, versus about $35 a year for RZG. Over long holding periods, that fee gap can compound meaningfully.
That said, RZG's recent outperformance isn't surprising given the type of stocks it holds. By concentrating on companies already showing strong sales and earnings momentum, growth-oriented funds like RZG tend to do well when those trends stay intact -- but that same concentration can cut both ways if momentum fades or a handful of its largest holdings stumble. ISCG's broader, market-cap-weighted approach spreads that risk across more than 900 companies, trading some upside potential for more diversified exposure to the small-cap growth space.
Investors who want the cheapest, most diversified way to own small-cap growth stocks may lean toward ISCG, while those comfortable with more concentrated bets on recent momentum, and willing to pay more for it, may find RZG's recent track record more appealing. As with any small-cap allocation, these funds are probably best used as a slice of a diversified portfolio rather than a core holding, given the added volatility that comes with smaller companies.
Before you buy stock in iShares Trust - iShares Morningstar Small-Cap Growth ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Trust - iShares Morningstar Small-Cap Growth ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,679! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!
Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 13, 2026. *
Andy Gould has positions in Sterling Infrastructure. The Motley Fool has positions in and recommends Guardant Health, Okta, and Sterling Infrastructure. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"RZG's superior risk-adjusted track record outweighs ISCG's cost and diversification edge in a continuing growth regime, but neither is compelling at current small-cap valuations."
The article presents ISCG (0.06% expense ratio, 933 holdings) as the cheaper, safer diversified small-cap growth vehicle versus concentrated, momentum-driven RZG (0.35% fees, 125 holdings) that has outperformed 1- and 5-year (38.84% vs 27.53% 1-yr; $1,375 vs $1,298 on $1k). Yet it glosses over that RZG's lower max drawdown (38.33% vs 41.47%) and pure-growth methodology have compounded to superior results despite higher costs. Missing context: small-cap growth valuations remain elevated post-2023-2025 rally; broader ISCG's higher beta (1.22) signals greater systematic risk if rates stay higher longer or recession hits. The fee gap matters far less than return dispersion in this volatile segment.
If momentum persists into 2027, RZG's concentrated high-conviction bets on names like ACMR, POWL could widen its outperformance gap, making ISCG's diversification a drag and its 29bp fee savings irrelevant.
"In the small-cap space, active quality screening via RZG’s momentum methodology provides superior risk-adjusted protection compared to the broad, lower-quality exposure of ISCG."
The article frames this as a choice between 'cheap diversification' (ISCG) and 'momentum alpha' (RZG). However, it misses the structural risk: small-cap growth is currently a graveyard for companies with negative earnings. RZG’s methodology—screening for sales and earnings momentum—is a vital filter in a high-rate environment where 'growth at any cost' is punished. ISCG’s broader index includes hundreds of 'zombie' firms that lack the pricing power to survive higher-for-longer interest rates. While ISCG’s 0.06% expense ratio is attractive, you are essentially paying for exposure to lower-quality balance sheets. RZG’s higher cost is effectively a 'quality premium' that historically justifies itself during periods of market volatility.
The strongest case against RZG is that its momentum-based weighting creates a 'buy high' trap, where the fund becomes most concentrated in overextended stocks just before a mean-reversion event.
"RZG's outperformance is regime-dependent (momentum favors concentrated growth screens), not durable—ISCG's 0.29% fee advantage compounds to ~$290 per $10k over 10 years, which is real insurance against RZG's concentration risk if growth trends reverse."
This article frames a false choice between fee drag and performance. Yes, RZG's 1-year return (38.84%) beats ISCG (27.53%), but that's a momentum-driven outperformance in a specific market regime—not evidence of structural superiority. RZG's 1.04 beta versus ISCG's 1.22 is the real tell: RZG is *less* volatile despite higher returns, suggesting the outperformance came from factor tilts (growth/momentum), not skill. The 5-year data flips the script—ISCG's $1,298 per $1,000 invested beats RZG's $1,375 claim (verify: article states $1,375 for RZG, implying ISCG underperformed, but the math doesn't reconcile with stated 1-year returns). More critically: RZG's 125 holdings with top position at 3.7% (ACM Research) creates concentration risk that fee savings can't offset if growth momentum reverses.
RZG's recent 11-point outperformance over one year could reflect genuine alpha generation from its growth-screening methodology rather than mere momentum capture, and that edge might persist if small-cap growth fundamentals remain strong.
"Cost and diversification matter, but regime-dependent alpha means neither fund is a universal ‘better buy’—your choice should hinge on horizon, risk tolerance, and views on growth momentum."
The article highlights a cheap, diversified path (ISCG: 0.06% expense, ~933 holdings) vs a concentrated momentum tilt (RZG: 0.35% expense, ~125 holdings) and notes RZG’s stronger 1-year/5-year returns. Yet the data show ISCG has a higher 5-year max drawdown (41.47% vs 38.33%) and a higher beta (1.22 vs 1.04), suggesting more volatility even with breadth. The narrative glosses regime sensitivity: momentum can outperform in tech/healthcare uplift, but can snap hard in a drawdown. The Motley Fool promotions and small-AUM caveat for RZG (135.9M) also matter for liquidity and tracking. In sum, cost/diversification help long-horizon risk control, but alpha is regime-dependent and not universal.
If you believe growth/momentum lasts, RZG may keep outperforming despite higher cost and concentration; the article’s upside bias toward ISCG ignores potential alpha from a focused growth tilt. Also, RZG’s smaller AUM could spur tracking error in volatile periods.
"RZG's small AUM introduces liquidity premium that the panel has ignored, amplifying its drawdown risk beyond stated max-drawdown stats."
Claude's 5-year math critique is off: $1,375 vs $1,298 per $1k correctly reflects RZG's cumulative edge despite the 1-yr snapshot. More importantly, nobody flagged liquidity risk—RZG's $136M AUM versus ISCG's multi-billion scale means wider spreads and potential premium/discount volatility in a small-cap exodus. That compounds concentration risk when momentum reverses.
"RZG's high turnover creates hidden tax drag that likely offsets its momentum-driven alpha compared to the more efficient, passive ISCG."
Grok, you are right about liquidity, but everyone is ignoring the tax-loss harvesting implications of high-turnover momentum funds like RZG. RZG’s methodology forces frequent rebalancing, which likely triggers capital gains distributions that erode net-of-tax returns for taxable accounts—a hidden cost far exceeding the 29bps fee gap. While Gemini touts 'quality,' that turnover is a silent performance killer. ISCG’s passive, buy-and-hold structure is superior for long-term compounding, regardless of the current momentum-driven outperformance.
"Tax drag on RZG is speculative without turnover data; liquidity friction on $136M AUM is a concrete, quantifiable risk that affects both funds' real-world execution costs."
Gemini's tax-loss harvesting critique is sharp, but needs verification: RZG's actual turnover ratio isn't stated in the article. If it's <50% annually, tax drag is modest. More pressing: nobody quantified the liquidity premium Grok flagged. RZG's $136M AUM in small-cap growth means bid-ask spreads could easily exceed the 29bp fee gap during volatility spikes—a real cost that erodes both funds' returns, not just RZG's. That's the hidden fee nobody's pricing.
"Tax drag from RZG hinges on turnover; without turnover data, the tax impact of the higher fee remains unproven."
Gemini's tax-loss harvesting critique hinges on RZG's turnover, but turnover isn't disclosed. If annual turnover stays modest, tax drag may be small; heavy turnover could wipe out 20–30bp of net return. We need actual turnover ratio, tax-distribution history, and after-tax return data to judge whether the higher cost is economically justified. Until then, it's an unverified risk rather than a given advantage.
The panelists generally agreed that while RZG's higher fees and momentum-driven strategy have led to superior short-term returns, its higher risk, concentration, and potential tax drag make it a less attractive long-term option compared to the cheaper, more diversified ISCG.
ISCG's lower fees and broader diversification
Concentration risk and potential tax drag from high turnover in RZG